Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

eco animal health europe limited - tylvalozinas - antiinfectives sisteminio naudojimo, antibacterials sisteminio naudojimo, makrolidai - pheasants; chicken; turkeys; pigs - pigstreatment ir methaphylaxis enzootinė kiaulių pneumonija;gydymo kiaulių dauginimosi voverė (ileitis);gydymo ir methaphylaxis kiaulių dizenterija. chickenstreatment ir methaphylaxis kvėpavimo takų ligos, susijusios su mycoplasma gallisepticum viščiukų. pheasantstreatment kvėpavimo takų ligos, susijusios su mycoplasma gallisepticum. turkeystreatment kvėpavimo takų ligos, susijusios su tylvalosin jautrių padermių ornithobacterium rhinotracheale kalakutai.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - aksitinibas - karcinoma, inkstų ląstelė - baltymų kinazės inhibitoriai - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - meloksikamas - anti-inflammatory and anti-rheumatic products, non-steroids - horses; dogs; cats; cattle; pigs - Šunys: mažinti uždegimą ir skausmą, ūmus ir lėtinis raumenų ir kaulų sistemos sutrikimai. sumažinti pooperacinį skausmą ir uždegimą po ortopedinių ir minkštųjų audinių operacijų. katės: sumažinti pooperacinį skausmą po ovariohisterektomijos ir smulkiųjų minkštųjų audinių operacijų. palengvinimas lengvas ar vidutinio sunkumo pooperacinį skausmą ir uždegimą, po chirurginių procedūrų katės, e. ortopedijos ir minkštųjų audinių chirurgija. palengvinti skausmą ir uždegimą, ūminis ir lėtinis raumenų ir kaulų sistemos sutrikimų katės. galvijams: skirti naudoti ūmiose kvėpavimo takų infekcijose, naudojant atitinkamą antibiotikų terapiją, siekiant sumažinti klinikinius požymius. vartoti kartu su peroraliniu rehidracijos gydymu viduriu, kad sumažėtų klinikinių požymių daugiau kaip savaitės veršeliams ir jauniems, negyviems galvijams. papildomam gydymui ūminio mastito gydymui kartu su antibiotikų terapija. pooperacinio skausmo reljefas po veršelių atsikabinimo. kiaulės: skirtos neinfekciniams lokomotyvams gydyti, siekiant sumažinti šlaunikaulio ir uždegimo simptomus.. už adjunctive terapijos gydymo puerperal kraujo užkrėtimas ir toxaemia (karvių mastito-metrito-agalaktijos sindromas) su tinkama antibiotikų terapija. pooperacinio skausmo, susijusio su nedideliu minkštuoju audiniu, tokiu kaip kastracija, reljefas. arkliai: uždegimo sušvelninimas ir skausmo sumažėjimas tiek ūminiuose, tiek lėtiniuose skeleto ir raumenų sutrikimuose. dėl skausmo, susijusio su arklių kolikomis, reljefas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

virbac s.a. - gyvas susilpnintas pasiutligės virusas, sag2 padermė - gyvų virusinių vakcinų - raccoon dogs (nyctereutes procyonoides); red foxes (vulpes vulpes) - veiksminga raudonųjų lapių ir usūrinių šunų imunizacija, siekiant užkirsti kelią pasiutligės viruso infekcijai. apsaugos trukmė yra mažiausiai 6 mėnesiai.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antinavikiniai vaistai - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. pacientams su egfr ar Šarminiai teigiamas navikas mutacijų, taip pat turėtų būti gautas tikslinis gydymas prieš gaunant keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viiv healthcare bv - abacavir, lamivudine - Živ infekcijos - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - kivexa skiriamas kartu su antiretrovirusiniais vaistais, skirtais žmogaus imunodeficito viruso (Živ) infekcijai gydyti suaugusiems, paaugliams ir vaikams, sveriantiems ne mažiau kaip 25 kg. prieš pradedant gydymą su abacavir, tyrimas dėl vežimo hla-b*5701 alelių, turėtų būti atliekamas Živ infekuotų pacientų, nepriklausomai nuo jų rasinės kilmės. abacavir neturėtų būti naudojama pacientams, žinoma, atlikti hla-b*5701 alelių.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

teva pharma b.v.  - lamivudine zidovudinas - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - lamivudinas / zidovudinas teva yra skiriamas kartu su antiretrovirusiniais vaistiniais preparatais, skirtais žmogaus imunodeficito viruso (Živ) infekcijai gydyti.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoatas, metforminas hidrochloridas - cukrinis diabetas, 2 tipas - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir mankšta pagerinti glycaemic kontrolės pacientams, kai insulino per stabilią dozės ir metforminas vien nesuteikia pakankamos kontrolės glycaemic.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.